Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates. Its lead product for prostate cancer imaging, Illuccix® (TLX591-CDx), is a kit-based gallium-68 PSMA agent designed to simplify PET scan preparation in decentralized nuclear medicine settings. Telix is also advancing PSMA-targeted therapy using lutetium-177, as well as somatostatin receptor-directed compounds for neuroendocrine tumors. Other programs in earlier stages include radiolabeled antibodies and small molecules aimed at bladder, brain and renal cancers.

Headquartered in Melbourne, Australia, Telix maintains commercial and clinical operations across North America, Europe and Asia Pacific. The company has secured regulatory approvals and reimbursements in multiple regions for its imaging products, and is conducting pivotal trials in the U.S. and Europe to expand patient access. Telix collaborates with leading academic institutions and contract research organizations to support its global clinical development and aims to build a scalable manufacturing and distribution network for radiopharmaceuticals.

Since its founding in 2015, Telix has grown under the leadership of CEO Dr. Christian Behrenbruch, who brings experience in healthcare management and specialized radiopharmaceutical development. The management team combines expertise in drug development, nuclear medicine and commercial operations. Telix continues to explore strategic partnerships and licensing agreements to accelerate the adoption of targeted radiopharmaceuticals and establish a new standard of care for oncology patients.

Key Stats

• Today's Range: $10.97 to $11.15
• 50-Day Range: $6.55 to $11.24
• 52-Week Range: $6.28 to $18.49
• Volume: 89,212 shs
• Average Volume: 233,734 shs
• Market Capitalization: $3.74 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.13
• Consensus Rating: Moderate Buy

TLX Stock Analysis - Frequently Asked Questions

How have TLX shares performed this year?

Telix Pharmaceuticals' stock was trading at $7.49 at the beginning of 2026. Since then, TLX stock has increased by 48.1% and is now trading at $11.0950.

How were Telix Pharmaceuticals' earnings last quarter?

Telix Pharmaceuticals Limited (NASDAQ:TLX) posted its earnings results on Friday, February, 20th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.06. The business had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million.
Read the conference call transcript.

When did Telix Pharmaceuticals IPO?

Telix Pharmaceuticals (TLX) raised $202 million in an initial public offering (IPO) on Wednesday, November 13th 2024. The company issued 17,000,000 shares at a price of $11.87 per share.

Who are Telix Pharmaceuticals' major shareholders?

Top institutional shareholders of Telix Pharmaceuticals include Private Advisor Group LLC (0.05%).

How do I buy shares of Telix Pharmaceuticals?

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/20/2026
• Today: 5/05/2026
• AGM 2026: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: 1,184
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $21.13
• High Price Target: $22.50
• Low Price Target: $20.00
• Potential Upside/Downside: +91.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.08
• Current Ratio: 1.43
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $803.79 million
• Price / Sales: 4.66
• Cash Flow: $0.04 per share
• Price / Cash Flow: 267.06
• Book Value: $1.23 per share
• Price / Book: 8.98

Miscellaneous

• Outstanding Shares: 339,110,000
• Free Float: N/A
• Market Cap: $3.74 billion
• Optionable: N/A
• Beta: 0.08